| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -16,336 | -8,078 |
| Depreciation | 1,523 | 754 |
| Amortization of licensed right to use technology | 102 | 51 |
| Stock-based compensation | 3,352 | 1,577 |
| Amortization of debt discount and accretion of debt issuance costs | 133 | 54 |
| Change in fair value of warrant liability | 16 | 17 |
| Amortization of operating lease assets | 217 | 121 |
| Paid in kind interest | 837 | 389 |
| Provision for inventory losses | 239 | 104 |
| Foreign currency adjustments | 138 | 128 |
| Loss on disposal of fixed assets | -57 | -11 |
| Unrealized gain in marketable securities | 4 | 9 |
| Inventory | -492 | -188 |
| Accounts receivable | 182 | 94 |
| Other current assets and prepaid expenses | -941 | -617 |
| Accounts payable | -35 | -708 |
| Accrued expenses | 9 | 691 |
| Change in fair value of derivative liability | - | 0 |
| Operating lease liabilities | -170 | -49 |
| Net cash used in operating activities | -8,979 | -4,526 |
| Purchase of marketable securities | 3 | 3 |
| Proceeds from sale of marketable securities | 1,263 | 777 |
| Purchase of property and equipment | 444 | 198 |
| Net cash provided by investing activities | 816 | 576 |
| Proceeds from issuance of common stock through at the market offerings | 8,135 | 2,441 |
| Proceeds from the sale of common stock of neuronos | 500 | - |
| Proceeds from issuance of common stock through exercise of warrants | 2,868 | - |
| Issuance of common stock warrants | 90 | - |
| Proceeds from long-term loan | 2,000 | 2,000 |
| Payment of loans | 609 | 375 |
| Net cash provided by financing activities | 12,984 | 4,066 |
| Effect of exchange rate changes on cash and cash equivalents | 145 | 127 |
| Increase in cash, cash equivalents and restricted cash | 4,966 | 243 |
| Cash and cash equivalents at beginning of period | 4,896 | - |
| Cash and cash equivalents at end of period | 9,862 | - |
Beyond Air, Inc. (XAIR)
Beyond Air, Inc. (XAIR)